Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient

Emma DeLoughery, Brian Avery, Thomas Deloughery

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    In case of severe bleeding, the physician must rapidly and effectively halt bleeding without the risk of thromboembolic complications. Despite widespread use, no study has directly compared recombinant activated factor VII (rFVIIa), the rFVIIa and 3-factor prothrombin complex concentrate (PCC) combination (“combination”), and 4-factor PCC on their effectiveness in improving patient outcomes. This study examined the medical records of 299 patients, 65.2% on warfarin prior to admission, who received these hemostatic agents and were admitted to an ICU or through the emergency department at Oregon Health & Science University. Mortality, length of stay, change in international normalized ratio (INR), plasma use, and number of thromboembolic complications were used to assess effectiveness. In patients receiving warfarin, the combination group had the greatest decrease in INR as well as lowest overall INR, but experienced a higher number of clotting complications, while the rFVIIa group used the most plasma. Non-warfarin patients in the combination group had the shortest length of stay among survivors, but the rFVIIa group had the lowest mortality. Based on this data, it may be prudent to further study the use of rFVIIa in treating extreme bleeding in the non-warfarin patient, while this study supports other data that 4-factor PCC may be the most prudent for the warfarin patient. Am. J. Hematol. 91:705–708, 2016.

    Original languageEnglish (US)
    Pages (from-to)705-708
    Number of pages4
    JournalAmerican Journal of Hematology
    Volume91
    Issue number7
    DOIs
    StatePublished - Jul 1 2016

    Fingerprint

    Warfarin
    Retrospective Studies
    Hemorrhage
    International Normalized Ratio
    Length of Stay
    Factor VIIa
    Mortality
    Hemostatics
    Medical Records
    Survivors
    recombinant FVIIa
    prothrombin complex concentrates
    Hospital Emergency Service
    Physicians
    Health

    ASJC Scopus subject areas

    • Hematology

    Cite this

    @article{d55048e1ceb94155a7d588aed901614f,
    title = "Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient",
    abstract = "In case of severe bleeding, the physician must rapidly and effectively halt bleeding without the risk of thromboembolic complications. Despite widespread use, no study has directly compared recombinant activated factor VII (rFVIIa), the rFVIIa and 3-factor prothrombin complex concentrate (PCC) combination (“combination”), and 4-factor PCC on their effectiveness in improving patient outcomes. This study examined the medical records of 299 patients, 65.2{\%} on warfarin prior to admission, who received these hemostatic agents and were admitted to an ICU or through the emergency department at Oregon Health & Science University. Mortality, length of stay, change in international normalized ratio (INR), plasma use, and number of thromboembolic complications were used to assess effectiveness. In patients receiving warfarin, the combination group had the greatest decrease in INR as well as lowest overall INR, but experienced a higher number of clotting complications, while the rFVIIa group used the most plasma. Non-warfarin patients in the combination group had the shortest length of stay among survivors, but the rFVIIa group had the lowest mortality. Based on this data, it may be prudent to further study the use of rFVIIa in treating extreme bleeding in the non-warfarin patient, while this study supports other data that 4-factor PCC may be the most prudent for the warfarin patient. Am. J. Hematol. 91:705–708, 2016.",
    author = "Emma DeLoughery and Brian Avery and Thomas Deloughery",
    year = "2016",
    month = "7",
    day = "1",
    doi = "10.1002/ajh.24384",
    language = "English (US)",
    volume = "91",
    pages = "705--708",
    journal = "American Journal of Hematology",
    issn = "0361-8609",
    publisher = "Wiley-Liss Inc.",
    number = "7",

    }

    TY - JOUR

    T1 - Retrospective study of rFVIIa, 4-factor PCC, and a rFVIIa and 3-factor PCC combination in improving bleeding outcomes in the warfarin and non-warfarin patient

    AU - DeLoughery, Emma

    AU - Avery, Brian

    AU - Deloughery, Thomas

    PY - 2016/7/1

    Y1 - 2016/7/1

    N2 - In case of severe bleeding, the physician must rapidly and effectively halt bleeding without the risk of thromboembolic complications. Despite widespread use, no study has directly compared recombinant activated factor VII (rFVIIa), the rFVIIa and 3-factor prothrombin complex concentrate (PCC) combination (“combination”), and 4-factor PCC on their effectiveness in improving patient outcomes. This study examined the medical records of 299 patients, 65.2% on warfarin prior to admission, who received these hemostatic agents and were admitted to an ICU or through the emergency department at Oregon Health & Science University. Mortality, length of stay, change in international normalized ratio (INR), plasma use, and number of thromboembolic complications were used to assess effectiveness. In patients receiving warfarin, the combination group had the greatest decrease in INR as well as lowest overall INR, but experienced a higher number of clotting complications, while the rFVIIa group used the most plasma. Non-warfarin patients in the combination group had the shortest length of stay among survivors, but the rFVIIa group had the lowest mortality. Based on this data, it may be prudent to further study the use of rFVIIa in treating extreme bleeding in the non-warfarin patient, while this study supports other data that 4-factor PCC may be the most prudent for the warfarin patient. Am. J. Hematol. 91:705–708, 2016.

    AB - In case of severe bleeding, the physician must rapidly and effectively halt bleeding without the risk of thromboembolic complications. Despite widespread use, no study has directly compared recombinant activated factor VII (rFVIIa), the rFVIIa and 3-factor prothrombin complex concentrate (PCC) combination (“combination”), and 4-factor PCC on their effectiveness in improving patient outcomes. This study examined the medical records of 299 patients, 65.2% on warfarin prior to admission, who received these hemostatic agents and were admitted to an ICU or through the emergency department at Oregon Health & Science University. Mortality, length of stay, change in international normalized ratio (INR), plasma use, and number of thromboembolic complications were used to assess effectiveness. In patients receiving warfarin, the combination group had the greatest decrease in INR as well as lowest overall INR, but experienced a higher number of clotting complications, while the rFVIIa group used the most plasma. Non-warfarin patients in the combination group had the shortest length of stay among survivors, but the rFVIIa group had the lowest mortality. Based on this data, it may be prudent to further study the use of rFVIIa in treating extreme bleeding in the non-warfarin patient, while this study supports other data that 4-factor PCC may be the most prudent for the warfarin patient. Am. J. Hematol. 91:705–708, 2016.

    UR - http://www.scopus.com/inward/record.url?scp=84973872159&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84973872159&partnerID=8YFLogxK

    U2 - 10.1002/ajh.24384

    DO - 10.1002/ajh.24384

    M3 - Article

    C2 - 27074566

    AN - SCOPUS:84973872159

    VL - 91

    SP - 705

    EP - 708

    JO - American Journal of Hematology

    JF - American Journal of Hematology

    SN - 0361-8609

    IS - 7

    ER -